What is the recommended treatment and monitoring plan for a patient with StAR (lipoid adrenal hyperplasia)?

Treatment and Monitoring of Lipoid Adrenal Hyperplasia (StAR Deficiency)

All patients with lipoid adrenal hyperplasia require lifelong glucocorticoid and mineralocorticoid replacement therapy, with hydrocortisone 15-25 mg/day in divided doses and fludrocortisone 50-100 mcg/day as the cornerstone of treatment 1, 2.

Immediate Management

For patients presenting acutely with adrenal crisis (volume depletion, hypotension, hyponatremia, hyperkalemia, hypoglycemia):

• Administer IV hydrocortisone at stress doses immediately, before diagnostic test results are available 1
• Provide aggressive fluid resuscitation and electrolyte correction
• Do not delay treatment for confirmatory testing in critically ill patients

Glucocorticoid Replacement

Use hydrocortisone 15-25 mg/day divided into 2-3 doses, with the highest dose given upon awakening 1. For a two-dose regimen, give the second dose in early afternoon (2 hours after lunch); for three doses, split between morning, lunch, and afternoon 1.

Alternative options:

• Cortisone acetate 20-35 mg/day in divided doses 1
• Prednisolone 3-5 mg/day once or twice daily for patients with compliance issues 1
• Avoid dexamethasone due to difficulty with dose titration and risk of Cushingoid side effects 1

Mineralocorticoid Replacement

Start fludrocortisone at 50-100 mcg/day in adults (adjust for children based on weight) 1. Patients should not restrict salt intake 1.

Monitor replacement based on:

• Clinical assessment: salt craving, postural hypotension, edema 1
• Serum electrolytes (sodium, potassium) 1
• Blood pressure control 1

Monitoring Strategy

Glucocorticoid Monitoring

Use clinical assessment only—do not use hormonal monitoring 1. Evaluate:

• Body weight trends
• Postural blood pressure
• Energy levels
• Signs of glucocorticoid excess (weight gain, striae, moon facies) 1

Sex-Specific Considerations for 46,XX Patients

For 46,XX patients, consider GnRH analog therapy starting at early puberty (around age 10) followed by estrogen and progestin replacement to prevent ovarian complications 3. This represents emerging evidence from 2026 showing:

• Prevention of ovarian cyst formation and torsion (complications occurring in approximately one-third of patients) 3
• Leuprorelin acetate from ages 10-15 years, followed by transdermal estradiol and norethindrone 3
• Serial ovarian ultrasound monitoring to assess cyst size and ovarian volume 3

46,XY Patients

All 46,XY patients will have female external genitalia or disorders of sex development and require:

• Appropriate sex hormone replacement at puberty
• Individualized approach to gender assignment and hormone therapy 2, 4

Long-Term Monitoring

Monitor every 3-6 months for:

• Growth parameters (height, weight, BMI)
• Blood pressure (sitting and standing)
• Electrolytes (sodium, potassium)
• Signs of under-replacement: fatigue, hyperpigmentation worsening, weight loss, hypotension
• Signs of over-replacement: excessive weight gain, hypertension, cushingoid features
• Bone age assessment periodically in children 5
• Pubertal development and gonadal function 6

Special Situations

Pregnancy (for 46,XX patients)

• Monitor at least once per trimester for signs of glucocorticoid over- or under-replacement 1
• Increase hydrocortisone dose during third trimester based on clinical course 1
• Use hydrocortisone over other glucocorticoids; avoid dexamethasone 1

Stress Dosing

Increase glucocorticoid doses 2-3 fold during:

• Febrile illnesses
• Surgical procedures
• Significant physical stress
• Trauma

Critical Pitfalls to Avoid

• Never delay treatment in suspected adrenal crisis—the diagnosis of lipoid CAH typically presents with life-threatening adrenal insufficiency in infancy 2, 7
• Do not use hormonal levels (cortisol, ACTH) to titrate chronic replacement therapy 1
• Do not restrict dietary salt intake in these patients 1
• Be aware that non-classical forms can present later (even at 4 years) with hypoglycemic seizures rather than neonatal crisis 8
• Monitor for ovarian complications in 46,XX patients throughout adolescence and adulthood 3

The nonclassical phenotype appears more common than previously recognized, particularly in certain populations (Indian, Chinese), and may present with hyperpigmentation, failure to thrive, and hypoglycemia rather than acute crisis 8, 6. The p.Arg188Cys mutation appears particularly common in Indian populations, suggesting founder effects 6.